about
Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancersTreatment Individualization in Colorectal CancerHow many molecular subtypes? Implications of the unique tumor principle in personalized medicineSomatic mutations in exocrine pancreatic tumors: association with patient survivalNew challenges in perioperative management of pancreatic cancerLung Cancer Gene Signatures and Clinical PerspectivesRegorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.Liquid biopsy: monitoring cancer-genetics in the blood.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancerTumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancerAbsence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell CarcinomaMutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathwayPersonalized radiotherapy: concepts, biomarkers and trial designCRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancerRole of apoptosis in colon cancer biology, therapy, and preventionGene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Immunological Defects in Neonatal Sepsis and Potential Therapeutic Approaches.KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.Advanced-stage pancreatic cancer: therapy options.Targeting PI3K in Cancer: Any Good News?Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again.High-throughput, multiparameter analysis of single cells.Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistanceTargeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.Improved Targeting of Cancers with Nanotherapeutics.Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer.Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation.Which way is forward in the treatment of rectal cancer?
P2860
Q26751068-142EEA61-E08A-4CC1-AB39-C7858D5ED15BQ26776215-1074651E-2F19-4AB2-9601-AB3A90BEE276Q26992045-A798EB7C-D87E-4063-AF35-AD1F88EA8C94Q27852155-401F4F2D-C401-4CA7-9E50-9258BAB9C54EQ28082422-66CADC9E-0486-48B6-8999-A262E5BE4026Q28387769-2DC767BC-BB95-4032-8F52-5B19CAAF8F86Q33838524-0759A26B-E769-4739-888E-139FD705D520Q34356149-5DE1B571-1297-4527-8B13-B437CF4FD288Q34447986-13028294-1B16-440F-8AC6-6A302EBA2E30Q34485726-63DA82B6-3378-4329-8541-34D01E412A88Q34505944-5052AF3A-F100-466A-A48E-4A7052785EC6Q34607312-55E8BA26-29FC-4CCE-A9A9-7FC663EC4AE6Q34911031-8519296A-B5FF-43A7-BC79-8B16E1A9258DQ35026938-768A67B1-5492-41E5-9B51-A235FFDCD15EQ35213124-A93861FD-4956-4FC1-9407-1A182F121F80Q35897673-C246EA08-7B60-4E19-A7D1-B12E19F21C3CQ36235704-996158ED-D89F-4754-9016-167AFE021DA9Q36544662-CBDAB087-2DC2-4CA8-BD0D-F642C8462345Q36763844-C56A9446-AFB8-495C-AEB9-FF0AA9A1244DQ37297137-0E1E5FC3-9054-4330-8B08-2AF4B24594FCQ37331465-9369D5DA-2495-46A2-96EA-0983E3956AD8Q37343279-1C1BE023-9EDF-4249-B8F5-250AB2E8736CQ37369576-30E695A4-5C4D-4882-8B5B-F9B34E201885Q37627158-29153B89-E87A-477A-8B86-C06A4F3A3256Q37689595-54CB3E48-63BC-4587-AC28-BA17F87D8E70Q37987661-BEF17B6C-C2BB-4E24-AE69-4D73D14C984FQ38102914-B0575FBA-1E90-4746-9C61-547A78EF1FC9Q38105322-87A937B2-1F57-4304-8061-F03E751F5CD4Q38115209-8C0DA673-1032-4A0A-8943-57F4B1ED0DE2Q38167618-A7B7BEF7-2B23-45B2-B201-543E2A110E35Q38249332-AB8A418A-8ED1-45A2-83EC-2ED641C8E1CEQ38263008-56D510DF-9C86-4ED9-8700-9B0F64B1C5C5Q38710557-D228B6F4-43EE-4E89-93EB-46661C64A2F0Q38722567-EDC7CAEF-E4FD-4DA1-A6F0-F11826683955Q39098665-6B187DD5-9BA2-4DBD-8264-83D19CC1E26DQ39114835-EC7D0C36-C50B-4F21-A0FA-FA7684F7DC6EQ39356301-1C2633F1-535A-4754-9179-35B4B1F48233Q42109645-CF1B483E-622C-4DA6-A570-63FD77DA4B92Q44808305-C8179905-5374-4ECD-B131-348FE97683A5Q46504181-B056FA14-2B98-4B05-B32C-C0E88C08CFD3
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Targeted therapies: how personal should we go?
@en
Targeted therapies: how personal should we go?
@nl
type
label
Targeted therapies: how personal should we go?
@en
Targeted therapies: how personal should we go?
@nl
prefLabel
Targeted therapies: how personal should we go?
@en
Targeted therapies: how personal should we go?
@nl
P2860
P50
P1476
Targeted therapies: how personal should we go?
@en
P2093
Loredana Vecchione
P2860
P356
10.1038/NRCLINONC.2011.164
P407
P577
2011-11-15T00:00:00Z